• Inicio
  • Resultados de la búsqueda
  • Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Journal of global antimicrobial resistance (2017-07-25)
Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, Mariana Castanheira, Robert K Flamm
RESUMEN

This study provides an in vitro analysis of dalbavancin activity against isolates causing skin and skin-structure infections (SSSIs) in children. A total of 770 Staphylococcus aureus, 167 β-haemolytic streptococci (BHS), 42 coagulase-negative staphylococci (CoNS), 25 Enterococcus faecalis and 13 viridans group streptococci (VGS) were collected from children (<18years old) in the USA (2014-2015). Dalbavancin had MIC50/90 values of 0.03/0.06μg/mL against S. aureus and CoNS, including methicillin-resistant (MRSA) and -susceptible (MSSA) isolates. Dalbavancin MICs were 8-32-fold lower than those of daptomycin (MIC50/90, 0.25/0.5μg/mL), vancomycin (MIC50/90, 0.5/1μg/mL) and linezolid (MIC50/90, 1/1μg/mL) against MRSA. These agents showed 100.0% susceptibility against MRSA, and clindamycin also had a high (92.7%) susceptibility rate. Dalbavancin (MIC50/90, 0.03/0.06μg/mL) and daptomycin (MIC50/90, 0.25/0.5μg/mL) were the most active agents against CoNS. When tested against E. faecalis, dalbavancin was up to 32-fold more active than ampicillin (MIC50/90, ≤0.5/1μg/mL), daptomycin (MIC50/90, 1/1μg/mL), linezolid (MIC50/90, 1/2μg/mL) and vancomycin (MIC50/90, 1/2μg/mL). Dalbavancin (MIC50/90, 0.008/0.03μg/mL), ceftriaxone (MIC50/90, ≤0.06/≤0.06μg/mL) and penicillin (MIC50/90, ≤0.06/≤0.06μg/mL) were the most active against BHS. VGS isolates were susceptible to dalbavancin (MIC100, 0.03μg/mL), with MICs 32-64-fold lower than daptomycin (MIC50/90, 0.5/0.5μg/mL), linezolid (MIC50/90, 0.5/1μg/mL) and vancomycin (MIC50/90, 0.5/0.5μg/mL). Approved agents available for the treatment of SSSI in children are limited. Dalbavancin demonstrated potent in vitro activity against isolates causing SSSI in children. Developing dalbavancin for SSSI treatment in children is warranted, provided safety and tolerability are satisfactory.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Dalbavancin, ≥90% (HPLC)

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.